Page last updated: 2024-12-06

propylbenzilylcholine mustard

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Propylbenzilylcholine Mustard: An analog of benzilylcholine mustard. It is an alkylating nitrogen mustard analog that binds specifically and irreversibly to cholinergic muscarinic receptors and is used as an affinity label to isolate and study the receptors. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID37396
MeSH IDM0017782

Synonyms (12)

Synonym
benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, 2-((2-chloroethyl)propylamino)ethyl ester
propylbenzilylcholine mustard
2-[2-chloroethyl(propyl)amino]ethyl 2-hydroxy-2,2-diphenylacetate
bdbm82380
cas_36167-80-3
prbch
36167-80-3
0056ks5787 ,
unii-0056ks5787
benzeneacetic acid, .alpha.-hydroxy-.alpha.-phenyl-, 2-((2-chloroethyl)propylamino)ethyl ester
DTXSID90189732
Q27231320

Research Excerpts

Overview

Propylbenzilylcholine mustard (PrBCM) is a synthetic, potent muscarinic antagonist. PrBCM binds specifically and irreversibly by means of a covalent linkage to Muscarinic receptors.

ExcerptReferenceRelevance
"[3H]Propylbenzilylcholine mustard ([3H]PrBCM) is a synthetic, potent muscarinic antagonist, which binds specifically and irreversibly by means of a covalent linkage to muscarinic receptors. "( Muscarinic receptors in the central nervous system of the rat. I. Technique for autoradiographic localization of the binding of [3H]propylbenzilylcholine mustard and its distribution in the forebrain.
Birdsall, NJ; Burgen, AS; Field, PM; Hulme, EC; Raisman, G; Rotter, A, 1979
)
1.02

Treatment

ExcerptReferenceRelevance
"Treatment with propylbenzilylcholine mustard (PrBCM), to inactivate irreversibly muscarinic receptors, caused a large dose dependent rightward shift of the dose-response curve to three agonistic furtrethonium derivatives with a concomitant decrease in maximal response."( The effect of propylbenzilylcholine mustard on contraction and radioligand binding parameters of muscarinic receptors in guinea pig ileum.
Rodrigues de Miranda, JF; Salden, HJ; van Ginneken, CA, 1987
)
0.97

Dosage Studied

Treatment with propylbenzilylcholine mustard (PrBCM), to inactivate irreversibly muscarinic receptors, caused a large dose dependent rightward shift of the dose-response curve to three agonistic furtrethonium derivatives.

ExcerptRelevanceReference
" We interpret our data as indicating that: there is much greater receptor reserve in the coupling of muscarinic receptors to adenylate cyclase than to PI hydrolysis; this, rather than differences in receptor affinity underlies the disparate dose-response relationships for the two responses; and differences in the effects of weak agonist on the two responses may also reflect differences in receptor reserve."( Differences in muscarinic receptor reserve for inhibition of adenylate cyclase and stimulation of phosphoinositide hydrolysis in chick heart cells.
Brown, JH; Goldstein, D, 1986
)
0.27
" Treatment with propylbenzilylcholine mustard (PrBCM), to inactivate irreversibly muscarinic receptors, caused a large dose dependent rightward shift of the dose-response curve to three agonistic furtrethonium derivatives with a concomitant decrease in maximal response."( The effect of propylbenzilylcholine mustard on contraction and radioligand binding parameters of muscarinic receptors in guinea pig ileum.
Rodrigues de Miranda, JF; Salden, HJ; van Ginneken, CA, 1987
)
0.98
" The method used involved analysis of dose-response data before and after fractional inactivation of receptors with propylbenzilylcholine mustard."( Structural requirements for muscarinic receptor occupation and receptor activation by oxotremorine analogs in the guinea-pig ileum.
Ringdahl, B, 1985
)
0.48
" Reduction in mAChR number after PBCM treatment was determined by Scatchard analysis of specific [3H]-NMS binding sites and compared with the expected reduction (q values) calculated from dose-response curves for carbachol-stimulated IP3 formation before and after PBCM treatment."( Relationship between muscarinic receptor occupancy and response in rat parotid acinar cells.
Baum, BJ; Dai, Y, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (107)

TimeframeStudies, This Drug (%)All Drugs %
pre-199068 (63.55)18.7374
1990's35 (32.71)18.2507
2000's4 (3.74)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.34 (24.57)
Research Supply Index4.69 (2.92)
Research Growth Index4.04 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other105 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]